With these premises, we cannot rule out the possibility that a stratification of CLL patients’ samples based on SLC7A11/xCT expression could provide a clearer picture of PRIMA-1Met sensitivity in combination with SAS, allowing for better customization of therapeutic interventions. Here, SLC7A11 is linked to B-cell chronic lymphocytic leukemia.